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Abstract 
Objective 
To compare temporal changes in European Society of Cardiology (ESC) acute 
myocardial infarction (AMI) quality indicator (QI) attainment in the United Kingdom 
(UK) and Israel. 
Methods 
Data cross walking using information from the Myocardial Ischaemia National Audit 
Project (MINAP) and the Acute Coronary Syndrome in Israel Survey (ACSIS) for 
matching 2 month periods in 2006, 2010 and 2013 was used to compare country-
specific attainment of 14 ESC AMI QIs. 
Results 
Patients in the UK (n=17,068) compared with Israel (n=5,647) were older, more likely 
to be women, and had less diabetes, dyslipidemia and heart failure. Baseline 
ischaemic risk was lower in Israel than the UK (GRACE risk 110.5 vs. 121.0). 
Overall, rates of coronary angiography (87.6% vs. 64.8%) and percutaneous coronary 
intervention (70.3% vs. 41.0%) were higher in Israel compared with the UK. 
Composite QI performance increased more in the UK (1.0% to 86.0%) than Israel 
(70.2% to 78.0%). Mortality rates at 30 days declined in each country, with lower 
rates in Israel in 2013 (4.2% vs. 7.6%).Composite QI adherence adjusted for GRACE 
risk score was inversely associated with 30-day mortality (OR 0.95, CI 0.95-0.97, 
p<0.001).  
Conclusions 
International comparisons of guideline recommended AMI care and outcomes can be 
quantified using the ESC AMI QIs. International implementation of the ESC AMI QIs 
may reveal country-specific opportunities for improved healthcare delivery.   
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What is already known about this subject? The European Society of Cardiology 
has developed a suite of quality indicators for acute myocardial infarction. Increased 
quality indicator attainment for acute myocardial infarction is associated with 
decreased mortality.  
What does this study add? The European Society of Cardiology quality indicators 
for acute myocardial infarction may be used in nationwide continuous and snapshot 
registries to investigate between and within country care and outcomes for acute 
myocardial infraction 
How might this impact on clinical practice? Nationwide cardiovascular data 
interrogation may enable health systems to ascertain where quality improvements may 
be made for acute myocardial infarction such that premature death from 
cardiovascular disease is reduced.   
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Introduction 
 
The evaluation of quality of care that extends beyond clinical outcomes is of growing 
interest to hospitals, physicians, and patients[1,2]. Evidence suggests that measuring  
and reporting healthcare is associated with clinical improvements[3]. With this in 
mind, metrics have been developed by the American College of Cardiology and 
American Heart Association (ACC/AHA) to assess care quality and to serve as targets 
for quality improvement initiatives[4,5]. In 2016, The European Society of 
Cardiology (ESC) proposed 20 quality indicators (QIs) for acute myocardial 
infarction (AMI), based upon the ESC guidelines[6,7], spanning seven domains of 
care[8]. These QIs have been externally validated in national clinical registries of 
AMI and demonstrated a significant inverse association with mortality at 30 days and 
3 years[9,10].  
 
International consensus recommends the routine recording of demographic, 
treatments and outcomes data for AMI[5,6] . Accordingly, a number of countries 
participate in the continuous or snapshot data collection of AMI hospitalizations into 
clinical registries, including the United Kingdom (UK) Myocardial Ischaemia 
National Audit Project (MINAP)[11], and the Acute Coronary Syndrome in Israel 
Survey (ACSIS)[12],  among others[13,14]. Although international comparisons have 
revealed differences in early mortality and between-center variation in the provision 
of care following AMI, there are no studies of the temporal changes in care and 
outcomes between countries as measured according to published AMI QIs. This 
knowledge gap is important given the fact that AMI performance metrics are 
associated with delays to implementation of care, and potentially avoidable 
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deaths[9,10,15,16]. We therefore used data from the MINAP and ACSIS national 
AMI registries to assess the provision of care according to the ESC AMI QIs between 
2006 and 2013.  
 
 
Methods 
 
ACSIS 
ACSIS is a national acute coronary syndrome snapshot survey conducted in all 25 
cardiology departments in Israel since 1992 over a two-month period, every two to 
three years[12].  ACSIS prospectively collects data pertaining to all acute coronary 
syndrome hospitalizations using a pre-specified case record form. The forms, 
completed by unit physicians, are then transferred to a central database. The survey is 
governed and coordinated by the Working Group on Acute Cardiovascular Care, part 
of the Israeli Heart Society, in participation with the Israeli Association for 
Cardiovascular Trials (IACT). The data storage, maintenance and processing is 
performed by the IACT, which also reviews documents to ensure data validity.  
Mortality data during hospitalization, at 30 days, and at 1-year are determined for all 
patients from hospital charts and by matching identification numbers of patients with 
the Israeli National Population Register.  
 
MINAP 
MINAP is a comprehensive registry of ACS hospitalisations occurring in all acute 
National Health Service hospitals in England and Wales and is mandated by the UK 
Department of Health. Data regarding patient demographics, treatments and outcomes 
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are collected for each patient, prior to secure electronic transfer to a central database 
under the auspice of the National Institute for Cardiovascular Outcomes 
Research[11,17]. There, data are linked to the Office for National Statistics for vital 
status and anonymized before distribution for the purposes of service evaluation and 
research. MINAP undergoes annual data validation by participating hospitals and the 
dataset is reviewed biennially. Comparison of key elements of the two registries and 
their host health systems is provided in the supplementary appendix. 
 
Analytical cohorts 
For MINAP, the analytical cohort (n=17,518) was drawn from all MINAP patients 
DJHG\HDUV with a discharge diagnosis of AMI (n=733,864) between 2003 and 
2013 and, by means of data cross walking (i.e., ensuring good mapping of cohorts), 
cases aligned to the ACSIS snapshot time periods (years 2006, 2010 and 2013) were 
selected. For both cohorts, cases with missing mortality data were excluded (Figure 
1). Other than that there were no excluded patients. No data were transferred between 
countries.   
 
Quality indicators 
Full details of the ESC AMI QIs are provided in supplementary table S1[8]. Briefly, 
each of the 20 ESC AMI QIs was mapped to the respective UHJLVWU\¶V GDWDILHOGV WR
determine those available for derivation. Patient eligibility for care was derived 
according to the ESC AMI QI definitions[8]. Patients who were recorded as having 
declined treatment or in whom treatment was deemed inappropriate by treating 
physicians were considered ineligible, as were those with a documented 
contraindication for specific treatments, as defined in each country. Patients with 
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missing data were excluded from corresponding QIs. Denominators for each QI were 
calculated separately with the appropriate patient population such that, for example, 
in-hospital deaths were not included in QI 4 and 5 which concern medications 
prescribed at time of discharge from hospital.  
 
Domain 7 of the ESC QIs assesses quality of care by means of composite scores. 
These were calculated using both an opportunity and all-or-none methodology. The 
opportunity based score was calculated using an equal weight method based on the 
number of times particular care processes were performed (numerator) divided by the 
number of chances a patient had to receive that care (denominator). Patients achieved 
the composite score whether the received all of the care interventions they were 
eligible for. The opportunity composite score originally consisted of 12 measures, 
however, MINAP data only allows assessment of nine measures combined using an 
equal weight method[9]. Quality indicator inclusion and qualification is shown in 
Supplementary Table S2.  
 
Statistical methods 
Patient baseline characteristics were described using numbers and percentages for 
categorical data, and medians and inter quartile ranges (IQR) or means and standard 
deviations (SD) for continuous non-normally and normally distributed data 
respectively. To estimate the Global Registry of Acute Coronary Events (GRACE) 
risk score adjusted 30-day mortality, we used the predicted probabilities derived from 
a logistic regression model where the dependent variable was 30-day mortality and 
the independent YDULDEOH ZDVHDFKSDWLHQW¶V FDOFXODWHG *5$&( ULVN VFRUH For 
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MINAP and ACSIS,  the GRACE score was calculated using the mini-GRACE 
methodology which has been previously validated with MINAP data[18]. Validation 
of the ACSIS cohort is presented in the supplement. This method allows for the 
VXEVWLWXWLRQ RIµXVHRIORRSGLXUHWLF¶ IRU.LOOLS FODVV DQGFKURQLF UHQDO IDLOXUH LQ OLHX RI
creatinine concentration for those records with missing information. Specifically, for 
ACSIS, GRACE scores were recalculated from the raw data to ensure compatibility 
with the MINAP GRACE risk score method. A logistic regression model was fitted to 
quantify the association between each QI and 30-day mortality. In line with previous 
research, for the composite QI, performance was split into 3 categories: (1) <40% of 
eligible interventions received, (2) 40% to <80% of eligible intervention received, 
and (3) 80% of interventions received[9,19,20]. We excluded measures that had 30 
patients with complete data for either aspect of the QI. Analyses were conducted in 
parallel without international transfer of analytical cohort data using R version 2.3 (R 
Core Team, Vienna, Austria) and Stata MP Version 14.0 (StataCorp LP, TX, USA), 
with statistical significance determined at 5%.  
 
Ethics 
Data collection for all ACSIS surveys was approved at each hospital by the local 
institutional Ethics Review Committee. For this study, fully anonymized data were 
used, and no ethics approval was required. MINAP data used for the study were fully 
anonymized and, as such, ethical approval was not required under NHS research 
governance arrangements. The National Institute for Cardiovascular Outcomes 
Research (NICOR) which includes the MINAP database (Ref: NIGB: ECC 1-06 
(d)/2011) had support, under section 251 of the National Health Service Act 2006, to 
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use patient information for medical research without consent. The study was 
conducted in compliance with the Declaration of Helsinki. 
 
Results  
 
Patient and treatment characteristics 
There were 21,829 patients across the comparison periods, comprising 17,068 from 
the UK (78.2%) and 4,761 from Israel (21.8%). Patients admitted with AMI in the UK 
were older compared with Israel (mean age 69.3 (SD 13.9) years vs. 63.8 (13.1) 
years), more frequently were women (33.9% vs. 22.2%), had lower rates of diabetes 
(19.6% vs. 36.3%), dyslipidemia (33.0% vs. 69.5%), heart failure (5.2% vs. 8.5%) 
and chronic kidney disease (5.6% vs. 12.9%) (Table 1). In Israel, there were more 
patients with electrocardiographic ST-segment deviation (69.8% vs. 55%). In Israel, 
there were 2332 (49%) NSTEMI, compared with 10,567 (60.0%) NSTEMI in the UK.  
 
Whilst the rates of an invasive coronary strategy (coronary angiography (87.6% vs. 
64.8%), percutaneous coronary intervention (PCI) (70.3% vs. 41.0%) and coronary 
artery bypass (CABG) surgery (5.3% vs. 2.0%) were higher between 2006 and 2013 
in Israel compared with the UK, the prescription of guideline- indicated medications at 
the time of hospital discharge (for hospital survivors) varied by country ± being 
higher in the UK IRU ȕ-blockers (86.5% vs.79.4%) and angiotensin converting enzyme 
inhibitors (ACEi)/angiotensin receptor blockers (ARB) (84.7% vs. 76.1%).  
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Ischaemic risk 
The GRACE score was lower for patients with AMI in Israel compared with the UK 
(110.5 vs 121.0). This was driven by lower baseline ischaemic risk for ST-segment 
elevation myocardial infarction, STEMI (96.6 vs 122.3) rather than non-STEMI 
(NSTEMI) (123.1 vs. 120.2) in Israel compared with the UK and, in turn, influenced 
by a higher age for STEMI in the UK than Israel (mean age 65.8 years vs 61.5 years) 
(Figure 2). 
 
Temporal trends in patient and treatment characteristics  
In Israel from 2006 and 2013, there was an increase in the proportion of patients with 
hypertension (57.1% vs. 65.0%), diabetes (32.3% vs. 39.6%), and dyslipidaemia 
(69.5% vs. 74.1%), and a decrease in peripheral vascular disease (10.1% vs. 7.9%). 
Fewer patients presented with ST-segment deviation (72.9% vs. 65.8%) and were 
more frequently in Killip class I (80.1% vs. 87.2%). The rates of coronary 
angiography (83.3% vs. 89.7%) and PCI (65.7% vs. 73%) increased from a high 
baseline in 2006.  
 
In the UK, there was a decline in the proportion of patients with a prior history of 
AMI (36.4% vs. 32.4%), family history of ischaemic heart disease (33.0% vs. 28.8%) 
and cerebrovascular disease (9.4% vs. 7.8%), and an increase in dyslipidemia (30.9% 
vs. 33.2%) and chronic kidney disease (3.6% vs. 6.5%). There was an increase in the 
proportion of patients presenting to hospital after an out of hospital cardiac arrest 
(1.7% vs. 2.9%) and fewer patients with ST-segment deviation (58.7% vs. 53.8%). 
There was an increase in the proportion of patients with a high GRACE risk score 
(22.8% vs. 26.3%). The rates of coronary angiography more than doubled (37.3% vs. 
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85.5%) and rates of PCI more than quadrupled (14.4% to 66.0%), both driven by an 
increase in primary PCI for STEMI (0.6% vs. 56.2% vs 80.3%) and an invasive 
coronary strategy for NSTEMI (35.9% vs. 63.9% vs. 78.5%).  
 
Quality Indicators 
Data cross walking between the two countries found that 14 of the 20 ESC AMI QIs 
were available for comparison in each country. Centre organization was not calculated 
as assumed 100% both in ACSIS and MINAP.  For QI 2.2c (door-in-door out) the 
split by year resulted in very small numbers and was omitted. Both MINAP and 
ACSIS allow the calculation of the GRACE risk score, however, as the QI specifies 
recording in the medical record, they were calculated as zero. The CRUSADE score is 
not currently recorded nor can it be calculated in MINAP or ACSIS, so calculated as 
zero. For QI 5.1 (secondary prevention with high-dose statins), discharge with statins 
was used for all patients (MINAP) or where not recorded (ACSIS) as surrogate. In 
addition, information regarding QI 6.1 (patient satisfaction) is not recorded in both 
registries and was omitted.  
 
In the UK between 2006 and 2013, the time and range of times to achieve arterial 
access for PPCI was reduced by at least half (80.4 (IQR 135) vs. 40.2 (31) minutes) 
and compared with Israel where access times and their ranges were stable (70.3 (68) 
vs. 67.0 (72) minutes). By contrast, in Israel a high proportion of NSTEMI received 
timely coronary angiography (83.8% in 2013) compared with the UK (64.1% in 
2013). The assessment of left ventricular function on discharge was higher in Israel 
(72.2% in 2013) despite temporal improvements in the UK (50.1% in 2013 vs. 22.1% 
in 2006). The prescription of P2Y12 inhibitors in the UK increased from its 
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introduction in 2006 (1.1%) to 94.9% of patients discharged with AMI in 2013 and 
compared with 77.4% in 2006 to 86.3% in Israel for the same period. In 2013, 
fondaparinux was rarely used in Israel with higher, yet modest, rates of use in the UK 
(2.4% vs. 49.5%). Healthcare performance as measured by the composite QIs 
increased in the UK from 46.2% in 2006 to 80.0% in 2013 (7.1, opportunity based 
score) and from 1.0% in 2006 to 86.0% in 2013 (7.2, all-or-none score), with no 
change in 7.1 (86.8% vs. 85.9%) and an increase in 7.2 in Israel (70.2% vs. 78.0%). A 
heat-PDS ILJXUH ZLWK SHUIRUPDQFH RIVHOHFWHG 4,¶VE\registry and year is presented in 
Figure 3. 
 
Mortality 
Crude 30-day and 1 year mortality rates declined more between 2006 and 2013 in the 
UK than in Israel (30-day: -3.2 vs,-1.6%; 1-year: -11.9% vs. ±2.3%), though at the 
end of the study period were higher in the UK than Israel at 30-days (7.8% vs. 3.8%) 
and at 1-year (10.1% vs.8.6%). After adjustment for baseline ischaemic (GRACE) 
risk, 30-day mortality rates decreased equally over the study period in the two 
countries (-0.6% and -0.5%, respectively), and were higher in the UK compared with 
Israel in 2013 (7.6% vs. 4.2%).  
 
In Israel, increasing opportunity-based composite QI attainment from low to 
intermediate to high was associated with decreasing 30-day mortality (61.0% vs. 
21.8% vs. 2.0%, p<0.001 for difference). Similarly, higher opportunity-based 
composite QI attainment, was associated with lower GRACE adjusted 30-day 
mortality (OR 0.95, 95% CI 0.95-0.97, p <0.001) with the magnitude and direction of 
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the effect remaining after further adjustment for year of hospitalisation (OR 0.98, 95% 
CI 0.97-0.98, p<0.001). 
 
This pattern was mirrored in the UK with a reduction in crude 30-day (43.2% vs. 
6.2% vs. 2.9% p<0.001 for low, intermediate and high attainment respectively) and 
one year mortality (53.8% vs. 17.0% vs 6.4% p<0.001 respectively).  Equally, 
opportunity-based QI attainment was associated with decrease in GRACE adjusted 
30-day mortality (OR 0.97, 95% CI 0.96-0.97 p<0.001) which also remained after 
adjustment for year of hospitalisation (OR 0.97 95% CI 0.95-0.97, p<0.001). Similar 
results were observed when examining 1-year mortality in 30-day survivors against 
QI attainment percentage (OR 0.98, 95% CI 0.97-0.98, p<0.001 for both cohorts). 
 
 
Discussion 
 
In this international study, we used the ESC AMI QIs to compare temporal changes in 
the delivery of healthcare across Israel and the UK. We found that in Israel patients 
with AMI tended to be younger, had a lower baseline ischaemic risk, more frequently 
received an invasive coronary strategy and had lower mortality rates compared with 
the UK. Even so, we noted a rapid upturn in the UK in the attainment of guideline-
indicated care as quantified by the ESC AMI QIs. Moreover, this study provides 
evidence for the application of the ESC AMI QIs for comparative evaluation of AMI 
healthcare delivery to highlight where in health systems they may be opportunities for 
quality improvement and, therefore, improved clinical outcomes for AMI.  
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We found that adherence to the ESC AMI QIs improved in both countries, and more 
so in the UK from 2006 to 2013. Part of the improvement in the UK could be 
attributed to slower adoption of guideline recommended care. In both countries, there 
was lower proportion of electrocardiographic ST-segment deviation at the time of 
admission to hospital, likely related to increased use of troponins and of higher 
sensitivity. In Israel, a high proportion of NSTEMI received timely coronary 
angiography, which may be explained by the fact that in Israel, all hospitals but one 
that receive patients with ACS have on-site 24-hour-7-days-a-week catheterization 
laboratories. For the UK, timely coronary angiography and PCI for NSTEMI and 
STEMI increased. This may be attributed, in part, to comprehensive tracking and 
auditing of clinical care, timely publications of center performance[21] and through 
local, regional, and national network quality improvement exercises[22]. This may 
also explain the improvement in QI attainment in the UK, in addition to the 
availability of specific treatments through the NHS. Indeed, the later adoption of 
DAPT in the UK compared to Israel demonstrates the influence of system decisions 
(e.g. approval/funding of certain drugs) in adoption and compliance with guideline 
recommended therapy. Going forward, Israel could, therefore, aspire to improving 
times to PCI for STEMI, whilst for the UK timely greater access to and timely 
revascularization for NSTEMI deserves greater attention. Both countries require 
improved assessment of LV function.  
 
Over the study period, as adherence to guideline- indicated care improved in each 
country, we noted a corresponding decline in mortality. Indeed our findings are in line 
with earlier research from the UK[9,18] and France[13] that separately reported a 
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statistically significant inverse association between ESC AMI QI attainment and early 
and late mortality. 
 
Despite substantial improvements in treatment and associated survival[23], global 
burden of AMI remains high. Recently, the ESC Atlas project highlighted major 
between country differences in cardiovascular health, delivery and standardized 
outcomes across Europe[24,25]. Earlier work found that the rates of adoption of 
cardiovascular health technologies such as primary PCI for STEMI vary between and 
within countries[26,27], and that missed opportunities in the provision of AMI 
guideline-indicated care were associated with excess mortality[15,28]. Notably, the 
LPSRUWDQFH RIµPHDVXULQJ WRLPSURYH FDUH¶KDVEHHQ HPSKDVL]HG E\RUJDQL]DWLRQV[1] 
as well as by international guidelines, and is a first necessary step in any attempt to 
reduce variation in cardiovascular disease. Whilst earlier research has revealed 
disparities in early mortality, suggested to be attributable to level of care, these studies 
did not map care to internationally recognized performance indices[29,30]. To our 
knowledge, our study is the first time that internationally recognized AMI QIs have 
been used to compare the levels of provision of guideline- indicated care between two 
countries. Thus, our investigation may serve as an example and incentive to record 
and report, both general patient data regarding AMI on a national and hospital level, 
and of QIs, in order to improve patient care and reduce the burden of disease. 
 
Although this work has strengths, one must appreciate its limitations. Each registry 
has its own data definitions, mechanisms for identifying potential participants, and 
data recording. The GRACE and CRUSADE scores were not recorded in either 
registry, nor was patient satisfaction. Assessment of left ventricular systolic function 
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for UK participants was low, and for Israel declined, which may have reduced the 
available data for assessment of an eligible population for receipt of ACE-inhibitors 
and ß-blockers. Another weakness is the perception of causation arising from the 
inverse association between attainment of care and outcomes ± we describe 
association with mortality and not causation. It is certainly possible that other factors 
may explain and contribute to this association such as lower risk patients receiving 
more treatments compared with sicker patients with an unrecorded contraindication 
receiving fewer. In this context, the expected reduction in mortality should be 
assessed according to relevant RCTs and not this investigation of care quality.  
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Figure 1 ± Flow diagram 
 
Figure 2 - Temporal changes in baseline ischemic risk (GRACE risk score) from 2006 to 
2013 for non-ST and ST segment elevation myocardial infarction, and both. 
 
Figure 3 ± Proportion of quality indicator adherence by registry and year 
ACEi ± Angiotensin converting enzyme inhibitor, ARB- angiotensin receptor blocker, BB- 
Beta blockers, NSTEMI: non-ST segment elevation myocardial infarction; STEMI: ST 
segment elevation myocardial infarction 
 
  
Table 1- Baseline and treatment characteristics 
  Israel UK 
  
Total cohort Years Total cohort Years 
(n=4761) 2006 (n=1731) 2010 (n=1539) 2013 (n=1491) (n=17,608) 
2006 
(n=5,171) 
2010 
(n=6,765) 
2013 
(n=5,672) 
Demographics 
 
Age in years, mean (SD) 63.8 (13.1) 63.5 (13.3) 63.6 (12.9) 64.1 (13.0) 69.3 (13.9) 70.0 (13.6) 68.9 (14.0) 69.1 (14.1) 
Age in years, median 
(IQR) 
63 (54.0-
74.0) 
63 (53.0-74.0) 63 (54.0-73.0) 64 (55.0-74.0) 
70.5 (59.0-
80.3) 
71.6 (59.0-
80.6) 
70.0 (59.0-
80.0) 
70.0 (58.3-
80.4) 
Female 
 1059 (22.2)    384 (22.2)    328 (22.0)    347 (22.5)  5954 (33.9) 1818 (35.3) 2240 (33.1) 1896 (33.5) 
Medical history 
 
Prior myocardial infarction 
 1366 (28.7)    469 (27.1)    448 (30.0)    449 (29.2)  6068 (34.5) 1882 (36.4) 2351 (34.8) 1835 (32.4)* 
Hypertension 
 2946 (61.9)    986 (57.1)    960 (64.4)   1000 (65.0)* 8120 (49.5) 2388 (48.5) 3084 (49.9) 2648 (50.0) 
Diabetes 
 1725 (36.3)    559 (32.3)    556 (37.3)    610 (39.6)* 3290 (19.6) 881 (19.9) 1282 (19.9) 1127 (20.7) 
Dyslipidaemia 
 3309 (69.5)   1076 (62.3)   1093 (73.3)   1140 (74.1)*  5273 (33.0) 1451 (30.9) 2091 (34.5) 1731 (33.2)* 
Family history of IHD 
 1213 (25.5)    414 (24.0)    417 (28.0)    382 (24.8)*  4192 (31.3) 1186 (33.0) 1688 (32.4) 1318 (28.8)* 
1 
 
Smoker (current or 
previous) 
 2941 (62.5)   1064 (62.4)    948 (64.7)    929 (60.4)  
10159 (62.9) 2990 (64.7) 3916 (62.8) 3253 (61.4)* 
Peripheral vascular disease 
  429 (9.0)    175 (10.1)    132 (8.9)    122 (7.9)* 700 (4.4) 220 (4.6) 261 (4.3) 219 (4.2) 
Heart  failure 
  405 (8.5)    149 (8.6)    134 (9.0)    122 (7.9)  837 (5.2) 256 (5.4) 315 (5.1) 266 (5.1) 
Chronic kidney disease 
  612 (12.9)    221 (12.8)    181 (12.1)    210 (13.6)*  897 (5.6) 171 (3.6) 386 (6.3) 340 (6.5)* 
Cerebrovascular disease 
  400 (8.4)    156 (9.0)    119 (8.0)    125 ( 8.1)*  1375 (8.5) 447 (9.4) 518 (8.5) 410 (7.8)* 
Clinical Presentation 
 
Out of hospital cardiac arrest 
  160 (3.4)     58 (3.4)     42 (2.8)     60 (3.9)  371 (2.2) 83 (1.7) 131 (2.0) 157 (2.9)* 
ST deviation on admission 
 3323 (69.8)   1260 (72.9)   1051 (70.5)   1012 (65.8)*  9203 (55.0) 2824 (58.7) 3410 (53.1) 2969 (53.8)* 
Killip class 
 
I 
 3946 (84.0)   1384 (80.1)   1273 (85.4)   1289 (87.2)*  3301 (79.4) 
 
2 (66.7) 3299 (79.4) 
II   424 (9.0)    199 (11.5)    115 (7.7)    110 (7.4)*  571 (13.7) Not available 0 (0) 571 (13.8) 
III   239 (5.1)    115 (6.7)     71 (4.8)     53 (3.6)* 226 (5.4) 
 
1 (33.3) 225 (5.4) 
IV    89 (1.9)     30 (1.7)     32 (2.1)     27 (1.8)  59 (1.4) 
 
0 (0) 59 (1.4) 
2 
 
GRACE score, mean (SD) 110.5 (34.0) 111.9 (35.2) 109.4 (33.9) 110.2 (32.9) 121.0 (34.4) 123.6 (31.6) 120.8 (34.7) 121.1 (34.2) 
GRACE STEMI, mean (SD) 96.6 (29.3) 97.5 (30.6) 96.9 (29.7) 95.5 (27.5) 122.4 (33.6) 137.1 (31.2) 122.7 (33.8) 121.9 (33.3) 
GRACE NSTEMI, mean (SD) 123.1 (33.1) 123.9 (34.4) 122.4 (33.0) 122.8 (31.9) 120.2 (34.8) 117.9 (30.3) 119.9 (35.0) 120.7 (34.6) 
Low risk GRACE category 2050 (51.7) 660 (50.8) 720 (53.2) 670 (50.9) 3913 (43.9) 23 (40.4) 2062 (43.7) 1828 (44.2) 
Medium risk GRACE category 1078 (27.2) 352 (27.1) 353 (26.1) 373 (28.3) 2665 (29.9) 21 (36.8) 1421 (30.1) 1223 (29.5) 
High risk GRACE category 782 (19.72) 277 (21.5) 261 (19.6) 244 (19.0) 2341 (26.3) 13 (22.8) 1239 (26.2) 1089 (26.3) 
In-hospital revascularisation   
&RURQDU\DQJLRJUDSK\ 
 4168 (87.6)   1439 (83.3)   1349 (90.5)   1380 (89.7)*  10218 (64.8) 1926 (37.3) 4316 (72.7) 3976 (85.5)* 
PCI 
 3344 (70.3)   1135 (65.7)   1086 (72.8)   1123 (73.0)*  6325 (41.0) 711 (14.4) 2776 (52.5) 2838 (66.0)* 
CABG surgery   254 (5.3)    106 (6.1)     64 (4.3)     84 (5.5)  321 (2.0) 75 (1.5) 149 (2.5) 97 (2.1)* 
Medications at discharge   
Aspirin 
 4460 (93.7)   1606 (92.8)   1405 (94.2)   1449 (94.2)  12634 (89.1) 3635 (81.4) 4853 (91.2) 4146 (94.4)* 
P2Y12 inhibitor 
 3871 (81.3)   1279 (73.9)   1269 (85.1)   1323 (86.0)*  8762 (62.4) 51 (1.1) 4731 (91.4) 3980 (94.9)* 
3 
 
ȕ-blocker 
 3782 (79.4)   1387 (80.1)   1201 (80.5)   1194 (77.6)  11166 (86.5) 2916 (73.7) 4,396 (90.3) 3854 (94.3)* 
Statin  
 4458 (93.6)   1589 (91.8)   1439 (96.5)   1430 (92.9)  13079 (90.9) 3916 (85.4) 4990 (92.7) 4173 (94.4)* 
ACEi/ARB  
 3625 (76.1)   1261 (72.8)   1184 (79.4)   1180 (76.7)*  11436 (84.7) 3210 (74.2) 4486 (88.7) 3740 (91.0)* 
     
    Values are presented as n (%) unless otherwise stated. 
ACEi ± Angiotensin converting enzyme inhibitor, ARB- angiotensin receptor blocker, IHD- ischaemic heart disease. 
  IQR- interquartile range, SD- standard deviation, PCI- percutaneous coronary intervention 
* Denotes p<0.05 compared to 2006. 
 
 
 
  
4 
 
Table 2 ± Quality indicators according to year and country 
    Israel United Kingdom 
QI QI Type 
Cohort 1 Cohort 2 Cohort 3 Cohort 1 Cohort 2 Cohort 3 
2006 (n=1731) 2010 (n=1539) 2013 (n=1491) 2006 (n=5,171) 2010 (n=6,765) 2013 (n=5,672) 
2.1: Proportion 
reperfused within 
12 hours (STEMI) 
Main 581 (96.2) 555 (96.0) 595 (95.0) 1141 (84.6) 1492 (90.8) 1405 (91.7)* 
2.2: STEMI timely 
reperfusion 
Main 236 (42.1) 299 (56.6) 294 (54.0)* 600 (50.6) 1017 (60.6) 1133 (72.3)* 
2.2a: fibrinolysis 
(<30 minutes) 
  19 (14.6) 7 (46.7) 10 (71.4)* 595 (50.6) 214 (52.2) 22 (45.8) 
2.2b: Primary PCI 
(<60 minutes) 
  213 (50.5) 214 (56.9) 246 (53.6) 5 (50.0) 803 (66.3) 1111 (74.9) 
2.3: NSTEMI Main 334 (59.4) 416 (81.2) 506 (78.1)* 79 (37.4) 292 (53.0) 358 (57.9)* 
5 
 
angiography <72 
hours 
2.3: NSTEMI 
angiography <72 
hours (no HR 
features) 
Main 227 (67.0) 295 (87.5) 341 (83.8)* 224 (41.7) 742 (58.9) 820 (64.1)* 
2.4: arterial access 
(STEMI),  minutes 
(median, IQR) 
Secondary 70.3 (43-115) 66.5 (39-111) 67.0 (35-107) 80.4 (30-165) 46.2 (31-71) 40.2 (29-60)* 
3.3: Assessment of 
LV function 
recorded in notes  
Main 1522 (87.9) 1181 (79.2) 1112 (72.3)* 1111 (22.1) 2550 (40.0) 2731 (50.1)* 
4.1: Proportion 
with adequate 
Main 1279 (77.3) 1269 (86.5) 1323 (86.3)* 51 (1.1) 4731 (91.4) 3980 (94.9)* 
6 
 
P2Y12 inhibition 
on discharge 
4.2: Proportion 
NSTEMI getting 
fondaparinux  
Main 0 (0) 0 (0) 46 (2.4) 0 (0) 562 (14.5) 1549 (49.5)* 
4.3: Proportion 
discharged on 
DAPT 
Secondary 1255 (72.2) 1242 (83.0) 1294 (83.4)* 47 (1.1) 4,477 (88.9) 3,819 (93.5)* 
5.1: Proportion 
discharged with 
statins 
Main 1589 (92.4) 1439 (96.6) 1430 (93.0) 3916 (85.4) 4990 (92.7) 4173 (94.4)* 
5.2: ACEI/ARB in 
those with HF or 
EF <40  
Secondary 232 (83.1) 189 (84.9) 160 (82.9) 1024 (77.3) 1473 (89.1) 1416 (92.0)* 
7 
 
ȕ- blocker in 
those with HF or 
EF <40  
Secondary 
  
239 (85.0) 
 
194 (88.8) 
 
158 (81.9) 845 (72.7) 1469 (91.9) 1499 (96.8) 
7.1: Main 
Composite QI 
(opportunity-
based) 
 
86.8 88.2 85.9 46.2 74.7 80.0* 
 7.2: Composite QI 
(all or none, 
overall score) 
 
70.2 81.4 78.0* 1.0 81.6 85.8* 
 7.2a: Composite 
QI (all or none, 3 
measures)1 , % 
 
73.5 83.2 79.7* 51.0 88.2 93.0* 
 7.2b: Composite 
 
54.0 70.9 65.5* 1.1 83.3 88.9* 
8 
 
QI (all or none, 5 
measures)1 , % 
7.3 Mortality at 
30-days adjusted 
for GRACE 
 5.1 4.7 4.2* 8.1 7.7 7.6* 
Crude mortality 
rate at 30-days 
 5.3 5 3.8* 11.0 7.5 7.8* 
Crude mortality at 
1 year 
 10.9 9.5 8.6 22.0 16.4 10.1 
 
ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin receptor blocker; DAPT- dual anti-platelet therapy; EF: ejection fraction; LV: left 
ventricle; NSTEMI: non-ST segment elevation myocardial infarction; PCI: percutaneous coronary intervention; QI- quality indicator; STEMI: ST segment 
elevation myocardial infarction
 
